CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it
has completed its previously announced call for redemption of $400
million in aggregate principal amount of 3.35% Convertible Senior
Subordinated Notes due 2015. Holders of $400 million in aggregate
principal amount of the 2015 Notes converted their 2015 Notes into
approximately 8.3 million shares of common stock prior to the June 17,
2013 redemption date. With the completion of this transaction, Vertex
has no outstanding convertible debt.
About Vertex
Vertex creates new possibilities in medicine. Our team discovers,
develops and commercializes innovative therapies so people with serious
diseases can lead better lives.
Vertex scientists and our collaborators are working on new medicines to
cure or significantly advance the treatment of hepatitis C, cystic
fibrosis, rheumatoid arthritis and other life-threatening diseases.
Founded more than 20 years ago in Cambridge, Mass., we now have ongoing
worldwide research programs and sites in the U.S., U.K. and Canada.
Today, Vertex has more than 2,000 employees around the world, and for
three years in a row, Science magazine has named Vertex one of
its Top Employers in the life sciences.
(VRTX - GEN)
Vertex (Investors):
Michael Partridge, 617-341-6108
or
Kelly
Lewis, 617-961-7530
or
Vertex (Media):
Zach
Barber, 617-341-6470
mediainfo@vrtx.com
Source: Vertex Pharmaceuticals Incorporated
News Provided by Acquire Media
